Sunday 13 July 2014
Olaparib is an inhibitor (PARP inhibitor) of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials.
It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast and prostate cancers.